Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AOTOJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
GMF-1A3-MMAE
|
|||||
| Synonyms |
1A3-MMAE; 1A3 MMAE; 1A3MMAE; GMF 1A3 MMAE
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.98
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-cleaved-AREG 1A3 Anti-ody
|
Antibody Info | ||||
| Antigen Name |
Amphiregulin (AREG)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 75.00% (Day 73) | Low HER2 expression (HER2+) | ||
| Method Description |
1A3-MMAE=5 mg/kg.
|
||||
| In Vivo Model | MCF7 breast cancer xenograft model | ||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 21) | Low HER2 expression (HER2+) | ||
| Method Description |
1A3-MMAE=5 mg/kg.
|
||||
| In Vivo Model | MCF7-F breast cancer xenograft model | ||||
| In Vitro Model | Invasive breast carcinoma | MCF7-F (fulvestrant resistant) cells | CVCL_0031 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.